Navigation Links
QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction

NEW YORK, Jan. 4 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Exchange-Traded Funds, a series of 20 underlying fund portfolios, today announced that effective at the opening of trading on Monday January 7, 2008, Alexion Pharmaceutical, Inc. (Nasdaq: ALXN) will replace Aspreva Pharmaceutical, Inc. (Nasdaq: ASPV) in the HealthShares(TM) Autoimmune-Inflammation Index. Alpharma, Inc. (NYSE: ALO) will also replace Aspreva Pharmaceutical, Inc. in the HealthShares(TM) Neuroscience Index. Aspreva Pharmaceutical is being acquired by Galencia Group (SWX: GALN). It was previously reported that Maxygen, Inc. would replace Asperva Pharmaceutical, Inc.

Companies included in the Autoimmune-Inflammation Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of inflammatory diseases such as osteoarthritis and autoimmune disorders including, but not limited to, rheumatoid arthritis, allergies, multiple sclerosis, psoriasis and lupus.

Companies included in the Neuroscience Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of neurological and psychiatric disorders including, but not limited to, Alzheimer's, Parkinson's, Huntington's, schizophrenia, anxiety, depression, epilepsy, pain and sleep disorders.

About HealthShares(TM)

XShares Advisors LLC, a financial services company based in New York, is the creator of the HealthShares(TM) family of Exchange Traded Funds (ETFs). HealthShares(TM) ETFs are organized into therapeutic 'Verticals' and represent specific areas of the healthcare, life science and biotechnology industries. Each Vertical addresses a distinct sub-segment of healthcare, such as the diagnosis and treatment of specific therapeutic areas (e.g. cardiology, cancer, infectious disease, etc.) and the development of medical devices (e.g. orthopedic repair, cardio devices, etc.). Each ETF tracks an index of 22-25 stocks and offers institutional and individual investors a more precise financial instrument that leverages the potential of healthcare investing while mitigating the risks of single stock picking. For more information, visit the company's website at:

About QED International Associates

QED International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at

SOURCE QED International Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. Baxter International Fourth Quarter 2007 Financial Results Conference Call
3. Statement of International Dairy Foods Association President and CEO Connie Tipton
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
6. International Substance Detection Firm IDenta To Release New Lead Test Kit - Rash Of Toy Incidents Leads Company To Enter New Marketplace
7. International Human Rights Day Recognized by Terasem Movement, Inc.s Third Annual Colloquium on the Law of Transbeman Persons
8. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
9. Chambers Joins PRA International as Senior Vice President of Human Resources
10. Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
11. Natural Nutrition Launches International Marketing Campaign for New All Natural Analgesic: BLUE LIGHTNING(TM) Fast Pain Relief
Post Your Comments:
(Date:10/13/2015)... JACKSONVILLE, Florida , October 13, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, will be a featured presenting company ... at the Wyndham Grand Hotel in ... --> TapImmune, Inc. (TPIV), a clinical-stage immunotherapy ...
(Date:10/13/2015)... Mass. and TORONTO , Oct. ... GNBT) today announced that it has entered into a non-binding ... ), a private Israeli company that has developed a proprietary ... infertile due to varicoceles. the United States ... between the ages of 25 and 44 diagnosed ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Clinovo recently ... expertise to the company’s fast growing clinical data solutions business. , Jeff Parr has ... companies of all sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... personalized medicine, is excited to announce their partnership with the Keck Medicine ... genetics of chronic pain. , The T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical ...
Breaking Biology Technology:
(Date:10/12/2015)... India , October 12, 2015 ... a new market research report on the "Digital Security ... technology, & Security Token), by Software (Anti-Phishing, Authentication, Network ... to 2020", published by MarketsandMarkets, the market is expected ... to 2020, and reach USD 14.6 Billion by 2020. ...
(Date:10/9/2015)... 2015 ... "Samsung Galaxy S6 Fingerprint Sensor - ... offering. --> ) has ... Galaxy S6 Fingerprint Sensor - Reverse Costing ... --> Research and Markets ( ...
(Date:10/7/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet ... term executive at American Express has been appointed to ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... the Wocket® smart wallet announces Mr. Stanley E. ...
Breaking Biology News(10 mins):